H
688767
vs
S
Shanghai Composite
Over the past 12 months, Hangzhou Biotest Biotech Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +53% compared to the Shanghai Composite's +25% growth.
Stocks Performance
688767 vs Shanghai Composite
Performance Gap
688767 vs Shanghai Composite
Performance By Year
688767 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hangzhou Biotest Biotech Co Ltd
Glance View
Hangzhou Biotest Biotech Co., Ltd. engages in the research and development, production and sales of point-of-care testing (POCT) diagnostic reagents. The company is headquartered in Hangzhou, Zhejiang and currently employs 622 full-time employees. The company went IPO on 2021-09-08. The firm's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
